Oral Wegovy approved
- The FDA approved oral Wegovy after positive Phase III OASIS‑4 results, expanding GLP‑1 treatment options. (appliedclinicaltrialsonline.com) - Novo Nordisk is preparing for a full U.S. launch, targeted for early January 2026. (appliedclinicaltrialsonline.com) - The approval adds an oral alternative to injectable GLP‑1 drugs, affecting treatment access and prescribing patterns. (appliedclinicaltrialsonline.com)
Wegovy now comes as a daily pill in the U.S., giving obesity patients and doctors a tablet option instead of weekly injections. (accessdata.fda.gov) The Food and Drug Administration added Wegovy tablets to the drug’s label in August 2025, and the current prescribing information lists a 25-mg oral dose taken once daily. The tablet is approved, like the injection, alongside a reduced-calorie diet and increased physical activity for adults with obesity or adults who are overweight with at least one weight-related condition. (accessdata.fda.gov) Wegovy belongs to a class of drugs called glucagon-like peptide-1, or GLP-1, receptor agonists, which mimic a gut hormone that helps people feel fuller and eat less. In the tablet’s pivotal OASIS 4 trial, 307 adults without diabetes were randomized 2-to-1 to oral semaglutide or placebo across sites in Canada, Germany, Poland, and the United States. (nejm.org) By week 64, patients on oral semaglutide had an estimated mean weight change of -13.6%, versus -2.2% on placebo. Gastrointestinal side effects were more common with the drug, with nausea, vomiting, diarrhea, constipation, and abdominal pain already listed in Wegovy’s prescribing information. (nejm.org) (accessdata.fda.gov) The label also carries the same boxed warning long used with semaglutide products: a thyroid C-cell tumor risk seen in rodents. Wegovy is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. (accessdata.fda.gov) Novo Nordisk’s 2025 annual report said the company had secured FDA approval and launch of Wegovy pill in the U.S. The company’s U.S. news archive later listed a March 31, 2026 press release for a multi-month subscription program covering “FDA-approved Wegovy,” a sign the commercial rollout had moved into broader access and pricing efforts. (annualreport.novonordisk.com) (novonordisk-us.com) The approval widens Novo Nordisk’s semaglutide lineup at a moment when the company is also expanding higher-dose injectable Wegovy. On March 19, 2026, the FDA approved Wegovy HD, a 7.2-mg injection, adding another dose option for adults seeking more weight loss. (fda.gov) For patients, the change is simple: the same brand that helped make weekly obesity shots mainstream is now also a pill, with the same need for long-term use, side-effect monitoring, and insurance coverage fights that have shaped the GLP-1 market. (accessdata.fda.gov)
